Alterity Therapeutics Ltd
Research Alterity Therapeutics Ltd (ATHE) on Bullrun: market cap USD 81.02M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerATHE
- ExchangeNASDAQ
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 81.02M
- Financial periodQ1 2026
- Free cash flow-AUD 4.73M
Valuation Snapshot
latest market cap is USD 81.02M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2024 | n/a | n/a | -AUD 16.65M | n/a | n/a | AUD 4.54M | AUD 105.83K | AUD 7.79M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 81.02M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 55.83M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 28.94M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 11.63M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 14.04M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 28.88M | n/a | n/a | n/a |
About Alterity Therapeutics Ltd
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Alterity Therapeutics Ltd's market cap?
Alterity Therapeutics Ltd's market capitalization is USD 81.02M.
What does Alterity Therapeutics Ltd do?
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease.